Vaxart Secures Financial Stability and BARDA Funding for Vaccine Development

Vaxart, Inc., a biotechnology company, has announced significant financial and strategic updates, ensuring its operational funding extends into 2026. This development comes alongside a major funding award from BARDA, which could reach up to $453 million, earmarked for advancing Vaxart’s COVID-19 and norovirus vaccine programs. The company’s innovative oral pill vaccine platform is set to transform vaccine administration by replacing injectables with more accessible pill forms, facilitating easier distribution and administration.

Vaxart plans to initiate a large-scale Phase 2b study comparing its oral COVID-19 vaccine to an FDA-approved mRNA vaccine, with initial results expected by early 2025. The company is also advancing its norovirus vaccine initiative, buoyed by positive Phase 1 results and pending further regulatory guidance.

For investors, these developments underline Vaxart’s robust financial positioning and its potential to lead in the evolving vaccine market. The support from BARDA validates the company’s approach and technology, promising significant implications for public health and shareholder value.